medonline
Interview with:
Leena Gandhi, MD, PhD
Interview by:
Dr. Gerhard Emrich
Produced by:
Mag. Oliver Eberhardt
Dr. Gerhard Emrich
17 Apr 2018

Leena Gandhi on the results of KEYNOTE-189

In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.

Leena Gandhi, MD, PhD, associate professor in the Department of Medicine and director of Thoracic Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health speaks about the results of KEYNOTE-189 that showed that the combination of immuntherapy and chemotherapy was significantly better in terms of ORR, PFS and OS compared with chemotherapy alone in patients with newly diagnosed metastatic NSCLC.

Reference:
Gandhi L et al., abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC